ArticleDiagnostic cytopathology2026
From Basics to Benchmarks: Evaluating Sample Adequacy, PD-L1 Expression, and Molecular Profiling in Effusion Samples of Lung Adenocarcinoma.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing. This study evaluates cytologic adequacy for molecular analysis, characterizes mutational and PD-L1 profiles, and correlates findings with survival outcomes.
methodsOver 10 years, a review of 2400 MPE identified 94 lung adenocarcinoma cases that underwent next generation sequencing (NGS). Patient demographics, cytological characteristics, molecular features, and survival outcome were integrated for analysis.
resultsThe mean effusion volume submitted for cytological and molecular testing was 589.8 mL (range 4-2790 mL) and mean tumor cellularity was 40% (range 10%-90%). NGS identified mutations in 86/94 cases (91%). TP53 was the most common alteration (42/94, 44.6%). FDA-approved biomarkers were detected: KRAS (28/94, 29.7%); EGFR (15/94, 15.9%); BRAF (8/94, 8.5%); ALK (3/94, 4.2%), ROS1 (2/94, 2.1%), RET fusions (1/94, 1%); and MET amplification (2/94, 2.1%). Smoking was associated with bloody effusions (p = 0.049), frequent TP53 mutations (p = 0.018), and fewer EGFR mutations (p = 0.012). Patients with effusions as primary presentation was associated with higher mortality (p = 0.002), frequent TTF-1 positivity (p = < 0.001) and frequent BRAF mutations (p = 0.049). TTF-1 positivity was associated with higher PD-L1 scores (p = 0.035). Survival was shorter in male patients (p = 0.045), smokers (p = 0.025), concurrent pericardial effusions (p = 0.027), and with TP53 mutation (p = 0.002).
conclusionsMolecular testing of effusion samples is feasible even at low fluid volumes, provided tumor cellularity is adequate. Prioritizing tumor fraction over volume ensures a higher likelihood of successful molecular analysis. Effusion-based NGS reliably identifies actionable alterations with diagnostic and prognostic relevance. Male patients, smokers, concurrent or primary presentation with MPE, and those with TP53 mutations had poorer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.